GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus
Abstract Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody again...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-023-00663-5 |
| _version_ | 1797429018764509184 |
|---|---|
| author | Gabrielle Scher Dennis A. Bente Megan C. Mears Maria N. B. Cajimat Matthias J. Schnell |
| author_facet | Gabrielle Scher Dennis A. Bente Megan C. Mears Maria N. B. Cajimat Matthias J. Schnell |
| author_sort | Gabrielle Scher |
| collection | DOAJ |
| description | Abstract Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody against the GP38 glycoprotein protected mice against lethal CCHFV challenge. To show that GP38 is required and sufficient for protection against CCHFV, we used three inactivated rhabdoviral-based CCHFV-M vaccines, with or without GP38 in the presence or absence of the other CCHFV glycoproteins. All three vaccines elicited strong antibody responses against the respective CCHFV glycoproteins. However, only vaccines containing GP38 showed protection against CCHFV challenge in mice; vaccines without GP38 were not protective. The results of this study establish the need for GP38 in vaccines targeting CCHFV-M and demonstrate the efficacy of a CCHFV vaccine candidate based on an established vector platform. |
| first_indexed | 2024-03-09T09:07:08Z |
| format | Article |
| id | doaj.art-764f01de94e7466ea07a9706c4bdfb7c |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T09:07:08Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-764f01de94e7466ea07a9706c4bdfb7c2023-12-02T09:58:59ZengNature Portfolionpj Vaccines2059-01052023-05-018111710.1038/s41541-023-00663-5GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virusGabrielle Scher0Dennis A. Bente1Megan C. Mears2Maria N. B. Cajimat3Matthias J. Schnell4Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityGalveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical BranchDepartment of Pathology, University of Texas Medical BranchGalveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical BranchDepartment of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson UniversityAbstract Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody against the GP38 glycoprotein protected mice against lethal CCHFV challenge. To show that GP38 is required and sufficient for protection against CCHFV, we used three inactivated rhabdoviral-based CCHFV-M vaccines, with or without GP38 in the presence or absence of the other CCHFV glycoproteins. All three vaccines elicited strong antibody responses against the respective CCHFV glycoproteins. However, only vaccines containing GP38 showed protection against CCHFV challenge in mice; vaccines without GP38 were not protective. The results of this study establish the need for GP38 in vaccines targeting CCHFV-M and demonstrate the efficacy of a CCHFV vaccine candidate based on an established vector platform.https://doi.org/10.1038/s41541-023-00663-5 |
| spellingShingle | Gabrielle Scher Dennis A. Bente Megan C. Mears Maria N. B. Cajimat Matthias J. Schnell GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus npj Vaccines |
| title | GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus |
| title_full | GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus |
| title_fullStr | GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus |
| title_full_unstemmed | GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus |
| title_short | GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus |
| title_sort | gp38 as a vaccine target for crimean congo hemorrhagic fever virus |
| url | https://doi.org/10.1038/s41541-023-00663-5 |
| work_keys_str_mv | AT gabriellescher gp38asavaccinetargetforcrimeancongohemorrhagicfevervirus AT dennisabente gp38asavaccinetargetforcrimeancongohemorrhagicfevervirus AT megancmears gp38asavaccinetargetforcrimeancongohemorrhagicfevervirus AT marianbcajimat gp38asavaccinetargetforcrimeancongohemorrhagicfevervirus AT matthiasjschnell gp38asavaccinetargetforcrimeancongohemorrhagicfevervirus |